Serum CA125 as a biomarker for dysmenorrhea in adenomyosis

Int J Gynaecol Obstet. 2023 Oct;163(1):131-139. doi: 10.1002/ijgo.14832. Epub 2023 May 12.

Abstract

Objective: To explore the association between CA125 and dysmenorrhea in adenomyosis, and the factors affecting CA125 in adenomyosis.

Methods: Patients were grouped a the presence of dysmenorrhea. The receiver operating characteristic (ROC) curve was applied to assess the utility of CA125 for dysmenorrhea. Binary logistic regression was employed to identify the factors associating dysmenorrhea and CA125 level.

Results: Patients in the dysmenorrhea group had higher CA125 levels than those in the non-dysmenorrhea group. For those with dysmenorrhea, CA125 levels of diffuse subtype group were higher than those of the focal subtype group. The CA125 level of 35 U/mL was validated as the optimal cut-point for dysmenorrhea in ROC curves. Compared with patients whose CA125 was 35 U/mL or less, those with CA125 levels greater than 35 U/mL were more likely to have dysmenorrhea. Thereafter, the multiple regression analysis showed that adenomyotic lesion volume was positively correlated with CA125 level in the total cohort and subtype groups, while age was negatively correlated with CA125 level in the total cohort and diffuse subtype.

Conclusions: The pathogenesis of adenomyosis is not clear. CA125 was associated with dysmenorrhea in adenomyosis, and, furthermore, CA125 level is positively correlated with the severity of the disease.

Keywords: CA125; adenomyosis; association; dysmenorrhea; inflammation; pathogenesis.

MeSH terms

  • Adenomyosis* / complications
  • Adenomyosis* / pathology
  • CA-125 Antigen
  • Dysmenorrhea / etiology
  • Female
  • Humans
  • Logistic Models

Substances

  • CA-125 Antigen